CHD vs CL: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of September 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CHD and CL share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CHD and CL exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Church & Dwight is an American consumer packaged goods company headquartered in Ewing, New Jersey, that makes household, personal-care and specialty products. It sells more than 80 brands, but roughly a dozen "power brands" (Arm & Hammer, OxiClean, Trojan, Nair, First Response, Orajel, Batiste, Waterpik, TheraBreath, Hero Cosmetics and others) drive the bulk of revenue. The mix blends slow-and-steady staples like baking soda and laundry additives with faster-growing personal-care acquisitions, and the company has a long track record of bolt-on M&A and consistent dividend increases.

Full CHD guide

Colgate-Palmolive is a global consumer-staples company that makes everyday household and personal-care products. It is a worldwide leader in oral care, where its Colgate-branded toothpaste, toothbrushes, and mouthwash hold a leading global share, and it also sells personal care (soaps, body wash, deodorants under brands like Palmolive, Softsoap, Irish Spring, and Sanex), home care (dish and surface cleaners such as Palmolive and Ajax), and pet nutrition through its Hill's Pet Nutrition business (Science Diet and Prescription Diet). Colgate makes money by selling these branded, frequently repurchased products at scale across more than 200 countries and territories, with a particularly large presence in emerging markets. Its competitive advantages come from powerful brands, vast distribution, and pricing power on staple goods. Headquartered in New York City, Colgate is a defensive, dividend-paying company whose products people buy regardless of the economic cycle.

Full CL guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• CHD drivers: Power-brand and personal-care mix; Margin expansion and productivity.
• CL drivers: Oral-care leadership and emerging markets; Hill's Pet Nutrition growth.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: U.S. For CL, colgate's growth is structurally slow: it competes in mature, saturated staples categories where volume gains are hard to come by and much of recent revenue growth has come from price increases that may not persist.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick CHD if you believe its drivers more; CL if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CHD and CL guides.

CHD. Q1 2026 net sales were about $1.47 billion (up 0.2%), with organic sales up 5.0% and adjusted EPS of $0.95, both ahead of the company outlook. Management targets roughly 3% to 4% organic growth and 5% to 8% adjusted EPS growth for 2026. The premium multiple reflects CHD's defensive profile and margin expansion, but it also assumes steady execution against soft domestic demand.

CL. Colgate trades at a premium consumer-staples multiple that reflects its defensive, recession-resistant cash flows, leading oral-care brands, the growth of Hill's, and a multi-decade dividend-raising record. The valuation premium is the market paying for stability and pricing power, balanced against the reality of slow underlying volume growth in mature categories.

Headline figures (approximate, July 2026): CHD shows revenue (ttm) ~$6.2B, market cap ~$23B, p/e (ttm) ~32x, eps (ttm) ~$3.04; CL shows revenue (ttm) ~$20 billion, operating margin ~20-21%, net income (ttm) ~$2.7 billion, dividend yield ~2-2.5% (Dividend King).

CHD and CL are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CHD and CL exposure against your real portfolio. It is not an investment adviser.